The New Drug for Alzheimer's

Laconimab was part of a US trial of around 1,800 people in the early stages of Alzheimer's disease. Those taking the drug over an 18 month period showed a 27% slower rate of decline than others in the trial. Some see these trial results as a potential triumphant turning point. We brought together three researchers to get their opinion.